Para diabetes tipo 2, algunos pacientes pueden lograr remisin con cambios intensivos de estilo de vida, permitiendo potencial reduccin del medicamento bajo supervisin mdica estricta
Clinical application of GLP-1 in fatty liver NAFLD is one of the most common metabolic syndromes in todays society and has become the common chronic liver disease that seriously affects the health of adults and even children worldwide
Finally, the cost savings demonstrated by this study may make the use of semaglutide attractive to payers, health maintenance organizations (HMOs), and others with a financial interest in outcomes in patients with T2D, although formal health care cost-effectiveness studies will be needed to balance the costs of the medication with the costs avoided owing to improved ASCVD outcomes
What the Latest Clinical Trial Results Show According to publicly reported late-stage trial data: Participants receiving higher doses achieved average weight loss approaching 2530% over approximately 68 weeks Some individuals lost more than 70 pounds during the study period Participants with obesity and knee osteoarthritis also reported significant reductions in joint pain These outcomes exceeded the average weight loss typically reported in clinical trials of currently approved GLP-1 medications
doi:10.5326/JAAHA-MS-5825
Great addition if you are considering this option
